Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-01-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
九届十九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various company matters such as asset disposal, guarantees, fixed asset purchases, and amendments to the company charter. The document includes voting counts and references to related announcements but does not contain financial statements or detailed management discussion. It is not an annual or interim report, nor an earnings release. It is not a proxy solicitation or AGM materials but specifically a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, confirming this classification.
2020-01-15 Chinese
房屋征收补偿价值评估报告书
Audit Report / Information Classification · 95% confidence The document is a detailed 房屋征收补偿价值评估报告书 (House Expropriation Compensation Value Assessment Report) for a property owned by 湘西华方制药有限公司. It includes extensive valuation details of land, buildings, decorations, and machinery, with specific valuation methods and results. The document is a formal valuation report prepared by a registered real estate appraisal company for government use in property expropriation compensation. It is not a corporate financial report, earnings release, management announcement, or regulatory filing. It is a standalone valuation report related to property assessment, which aligns best with an Audit Report / Information (AR) category, as it involves valuation and appraisal information separate from annual or interim financial reports. The document length is substantial and contains detailed valuation data, not merely an announcement or summary, so it is not RPA or RNS. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2019
2020-01-15 Chinese
关于全资子公司湘西华方制药有限公司土地及机器房屋处置的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the disposal of land and buildings of its wholly-owned subsidiary, Xiangxi Huafang Pharmaceutical Co., Ltd. It details the transaction with the local government for land and property expropriation and compensation. The document includes transaction overview, parties involved, asset details, financial data, and impact on company performance. It is a specific transaction announcement related to asset disposal and compensation, not a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly/yearly results but focuses on a capital asset transaction. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on a significant capital transaction affecting the company's assets and financial position.
2020-01-15 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled '昆药集团股份有限公司章程' which translates to 'Articles of Association of KPC Pharmaceuticals, Inc.' It contains detailed sections on company governance, shareholder rights, board structure, share issuance, share repurchase, and other corporate governance matters. The content is a comprehensive set of internal rules and regulations governing the company’s organization and behavior, including chapters on shareholders, board of directors, management, financial accounting, auditing, and social responsibility. There is no indication that this is a financial report, earnings release, or announcement. Instead, it is a governance document outlining the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-01-15 Chinese
九届十二次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, voting process, and the resolution passed regarding the disposal of land and machinery by a subsidiary. The document is short (514 characters) and serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements, audit information, or management discussion. It is not a regulatory filing or certification letter. The content fits best under Board/Management Information (MANG) as it relates to internal company governance decisions and board resolutions.
2020-01-15 Chinese
独立董事关于昆药集团九届十九次董事会相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding specific company matters: disposal of land and buildings by a subsidiary and provision of a bank credit guarantee for a sub-subsidiary. It discusses compliance with laws, fairness, and shareholder interests. The document is short (838 characters) and does not contain financial statements or detailed financial data. It is an opinion related to board matters but does not announce changes in board or management personnel. It is not a full audit report or annual/interim report. It is a regulatory disclosure related to corporate governance and compliance with listing rules, but it is not a governance report per se. Given the nature of the document as an independent directors' opinion on specific corporate matters, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-01-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.